Lead antibody MB0109 targets C1q and uniquely inhibits both classical complement cascade and C1q-mediated macrophage/microglial activation — two key drivers of neuroinflammationMB0109 demonstrated ...

Opportunities in the C5 inhibitors market include developing next-gen biosimilars and biosuperiors to improve administration frequency and expand treatment indications for diseases like aHUS, SCD, MG, ...

Our immune system works day and night to protect us from bacteria, viruses, and injuries. It is a complex defense network made up of many types of cells and proteins that cooperate to keep the body ...

Dianthus Therapeutics stock shot higher Monday after the company said it would advance its experimental CIDP treatment.

InflaRx (NASDAQ:IFRX) highlighted recent clinical updates and strategic priorities for its complement inhibition platform during a presentation at Oppenheimer’s 36th Annual Healthcare Life Sciences ...

Even as BAT expands beyond trial criteria, patients see gains in LVEF, symptoms, and more. A survival impact remains unclear.

Growing evidence suggests the gut microbiome may influence how patients respond to GLP 1 obesity drugs. Researchers are ...

A patient in China with hepatocellular carcinoma survived 171 days following xenotransplantation with a genetically modified ...

Early GO decision reached ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants ...

The 12-16-week open-label study evaluated Ruxoprubart as monotherapy in treatment-naïve PNH patients. Key findings include: CLEVELAND, March 09, 2026 (GLOBE NEWSWIRE) -- NovelMed Therapeutics Inc., a ...

Spinal cord injury often triggers a cascade of secondary damage that severely limits functional recovery, largely driven by ...

Comprehensive Enterprise Evidence-Based Patient Activation Intelligence Solution Connects Healthcare Value-Based Care Strategy to Measurable Results Across Access, Referral Closure, Care Transitions, ...